[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]acetonitrile | 194612-30-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: [1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]acetonitrile
• 英文别名: 2-(1-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperidin-4-yl)acetonitrile；2-[1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]acetonitrile
• CAS: 194612-30-1
• 化学式: C₁₆H₂₀N₂O₂
• 分子量: 272.347
• InChiKey: HWFQRZXFYPTATF-UHFFFAOYSA-N

物化性质

• 沸点：
  426.5±28.0 °C(Predicted)
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]acetonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]ethylcarbamic acid ethyl ester
  参考文献：
  名称：

  New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity

  摘要：

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.

  DOI：

  10.1021/jm991121g
• 作为产物：
  描述：

  2-羟甲基-1,4-苯并二噁烷对甲苯磺酸酯 、 2-(1-苄基-4-哌啶)乙腈 反应 20.0h， 以64%的产率得到[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]acetonitrile
  参考文献：
  名称：

  New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity

  摘要：

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.

  DOI：

  10.1021/jm991121g

文献信息

• New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity
  作者：Patrice Mayer、Pascale Brunel、Céline Chaplain、Christel Piedecoq、Francis Calmel、Philippe Schambel、Philippe Chopin、Thierry Wurch、Petrus J. Pauwels、Marc Marien、Jean-Louis Vidaluc、Thierry Imbert

  DOI：10.1021/jm991121g

  日期：2000.10.1

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.